West China School of Medicine, Sichuan University, Chengdu.
Cancer Biol Ther. 2011 Jul 1;12(1):86-92. doi: 10.4161/cbt.12.1.15730.
A new non-cytotoxic therapy that SOM230 (pasireotide)，a somatostatin analogue (SSTA) combined with celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor was tested in nude mice bearing HepG2 xenografts. Two agents did not markedly arrest the growth of HepG2 cells but greatly down-regulated vascular endothelial growth factor expression. An imbalance between the vigorous demand and insufficient supply of nutrients and oxygen for tumor growth resulted in the massive necrosis of xenografts. The combination synergistically induced the early apoptosis of HepG2 cells and achieved longest survival without adverse reaction. This impressive strategy appears promising as a systemic therapy for patients with hepatocellular carcinoma (HCC).
一种新的非细胞毒性治疗方法，即 SOM230（帕瑞肽），一种生长抑素类似物（SSTA）与塞来昔布联合应用，塞来昔布是一种选择性环氧化酶-2（COX-2）抑制剂，在裸鼠携带 HepG2 异种移植瘤中进行了测试。两种药物并没有明显阻止 HepG2 细胞的生长，但大大下调了血管内皮生长因子的表达。肿瘤生长对营养物质和氧气的旺盛需求与供应不足之间的失衡导致异种移植物发生广泛坏死。联合用药协同诱导 HepG2 细胞早期凋亡，且无不良反应，实现了最长的生存时间。这种令人印象深刻的策略似乎有望成为肝细胞癌（HCC）患者的全身治疗方法。
